Amplifying the Migraine Community's Voice in ICER's Value Assessment Process

During the past year, there’s been a clear shift in how patient organizations are engaging with the Institute for Clinical and Economic Review (ICER) and its value assessments of new, and often first-of-their-kind, medicines. These organizations have recognized the need to become involved earlier in the assessment process so that they have ample time to provide patient and stakeholder perspectives on important issues, such as what it’s like to live with a particular condition and how quality of life and work productivity are affected, and to shape the questions that ICER will address.

Read more.